Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending July 16, 2008. The report serves as a notification of transactions involving directors or persons discharging managerial responsibility, specifically regarding the Deferred Investment Award Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of a specific executive transaction rather than a financial performance report.
Material Changes
The only material change disclosed is an increase in the shareholding interest of Mr. S M Werner. This increase resulted from the re-investment of dividends paid to shareholders on July 10, 2008, at a price of $48.40 per ADR.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, risks, contingencies, or unusual items. It strictly details a transaction notified in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a).
Key Facts for Investor Verification
- Transaction Date: July 16, 2008.
- Executive Involved: Mr. S M Werner.
- Transaction Type: Increase in Ordinary share ADRs via dividend re-investment.
- Price per ADR: $48.40.
- Dividend Date: July 10, 2008.